Literature DB >> 25777573

Current treatment options for malignant peripheral nerve sheath tumors.

Diana Bradford1, AeRang Kim.   

Abstract

Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft tissue sarcomas characterized by high risk of local recurrence and distant metastasis. The only known curative therapy is complete resection. Adjuvant radiation is recommended for larger lesions or those with more aggressive histology. Given the dismal prognosis in tumors that cannot be cured by surgery alone and the lack of systemic therapy with proven benefit, targeted therapies based on knowledge of activation of the Ras pathway and downstream effectors have been trialed in MPNST, thus far without proven benefit. However, novel or combination therapies based on recent preclinical advances are highly desirable and are the subject of ongoing clinical trials.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25777573     DOI: 10.1007/s11864-015-0328-6

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  39 in total

1.  Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation.

Authors:  G P Nielsen; A O Stemmer-Rachamimov; Y Ino; M B Moller; A E Rosenberg; D N Louis
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  Postoperative nomogram for 12-year sarcoma-specific death.

Authors:  Michael W Kattan; Denis H Y Leung; Murray F Brennan
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

3.  Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.

Authors:  Eline Beert; Hilde Brems; Bruno Daniëls; Ivo De Wever; Frank Van Calenbergh; Joseph Schoenaers; Maria Debiec-Rychter; Olivier Gevaert; Thomas De Raedt; Annick Van Den Bruel; Thomy de Ravel; Karen Cichowski; Lan Kluwe; Victor Mautner; Raf Sciot; Eric Legius
Journal:  Genes Chromosomes Cancer       Date:  2011-08-24       Impact factor: 5.006

4.  Malignant peripheral nerve sheath tumours in neurofibromatosis 1.

Authors:  D G R Evans; M E Baser; J McGaughran; S Sharif; E Howard; A Moran
Journal:  J Med Genet       Date:  2002-05       Impact factor: 6.318

5.  TORC1 is essential for NF1-associated malignancies.

Authors:  Cory M Johannessen; Bryan W Johnson; Sybil M Genther Williams; Annie W Chan; Elizabeth E Reczek; Ryan C Lynch; Matthew J Rioth; Andrea McClatchey; Sandra Ryeom; Karen Cichowski
Journal:  Curr Biol       Date:  2007-12-27       Impact factor: 10.834

6.  Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

Authors:  Robert G Maki; David R D'Adamo; Mary L Keohan; Michael Saulle; Scott M Schuetze; Samir D Undevia; Michael B Livingston; Matthew M Cooney; Martee L Hensley; Monica M Mita; Chris H Takimoto; Andrew S Kraft; Anthony D Elias; Bruce Brockstein; Nathalie E Blachère; Mark A Edgar; Lawrence H Schwartz; Li-Xuan Qin; Cristina R Antonescu; Gary K Schwartz
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

7.  Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.

Authors:  Rashmi Chugh; J Kyle Wathen; Robert G Maki; Robert S Benjamin; Shreyaskumar R Patel; Paul A Meyers; Paul A Myers; Dennis A Priebat; Denise K Reinke; Dafydd G Thomas; Mary L Keohan; Brian L Samuels; Laurence H Baker
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

8.  Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.

Authors:  Gunnar Johansson; Yonatan Y Mahller; Margaret H Collins; Mi-Ok Kim; Takahiro Nobukuni; John Perentesis; Timothy P Cripe; Heidi A Lane; Sara C Kozma; George Thomas; Nancy Ratner
Journal:  Mol Cancer Ther       Date:  2008-05       Impact factor: 6.261

9.  Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model.

Authors:  Hongzhen Li; Susana Velasco-Miguel; William C Vass; Luis F Parada; Jeffrey E DeClue
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

Review 10.  Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.

Authors:  Matthias Kolberg; Maren Høland; Trude H Agesen; Helge R Brekke; Knut Liestøl; Kirsten S Hall; Fredrik Mertens; Piero Picci; Sigbjørn Smeland; Ragnhild A Lothe
Journal:  Neuro Oncol       Date:  2012-11-15       Impact factor: 12.300

View more
  18 in total

Review 1.  The NF1 gene in tumor syndromes and melanoma.

Authors:  Maija Kiuru; Klaus J Busam
Journal:  Lab Invest       Date:  2017-01-09       Impact factor: 5.662

Review 2.  Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside.

Authors:  Justin Korfhage; David B Lombard
Journal:  Mol Cancer Res       Date:  2019-04-25       Impact factor: 5.852

3.  Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.

Authors:  Lai Man Natalie Wu; Yaqi Deng; Jincheng Wang; Chuntao Zhao; Jiajia Wang; Rohit Rao; Lingli Xu; Wenhao Zhou; Kwangmin Choi; Tilat A Rizvi; Marc Remke; Joshua B Rubin; Randy L Johnson; Thomas J Carroll; Anat O Stemmer-Rachamimov; Jianqiang Wu; Yi Zheng; Mei Xin; Nancy Ratner; Q Richard Lu
Journal:  Cancer Cell       Date:  2018-02-12       Impact factor: 31.743

4.  Synovial Sarcoma of the Nerve-Clinical and Pathological Features: Case Series and Systematic Review.

Authors:  Stephen Shelby Burks; Ross C Puffer; Iahn Cajigas; David Valdivia; Andrew E Rosenberg; Robert J Spinner; Allan D Levi
Journal:  Neurosurgery       Date:  2019-12-01       Impact factor: 4.654

5.  Right Ventricular Involvement of an Aggressive Malignant Peripheral Nerve Sheath Tumor.

Authors:  Saikrishna Patibandla; Miklos Auber; Stell Patadji; Yasmin Hamirani
Journal:  J Radiol Case Rep       Date:  2022-01-01

6.  Experimental models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor.

Authors:  Angela D Bhalla; Sharon M Landers; Anand K Singh; Jace P Landry; Michelle G Yeagley; Gabryella S B Myerson; Cristian B Delgado-Baez; Stephanie Dunnand; Theresa Nguyen; Xiaoyan Ma; Svetlana Bolshakov; Brian A Menegaz; Salah-Eddine Lamhamedi-Cherradi; Xizeng Mao; Xingzhi Song; Alexander J Lazar; Ian E McCutcheon; John M Slopis; Joseph A Ludwig; Dina C Lev; Kunal Rai; Keila E Torres
Journal:  Lab Invest       Date:  2022-02-28       Impact factor: 5.662

7.  Clinical Outcome After Pencil Beam Scanning Proton Therapy of Patients With Non-Metastatic Malignant and Benign Peripheral Nerve Sheath Tumors.

Authors:  Nicolas Bachmann; Dominic Leiser; Alessia Pica; Barbara Bachtiary; Damien C Weber
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

8.  Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.

Authors:  Christine M Kivlin; Kelsey L Watson; Ghadah A Al Sannaa; Roman Belousov; Davis R Ingram; Kai-Lieh Huang; Caitlin D May; Svetlana Bolshakov; Sharon M Landers; Azad Abul Kalam; John M Slopis; Ian E McCutcheon; Raphael E Pollock; Dina Lev; Alexander J Lazar; Keila E Torres
Journal:  Cancer Biol Ther       Date:  2015-12-09       Impact factor: 4.742

9.  Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.

Authors:  Kelsey L Watson; Ghadah A Al Sannaa; Christine M Kivlin; Davis R Ingram; Sharon M Landers; Christina L Roland; Janice N Cormier; Kelly K Hunt; Barry W Feig; B Ashleigh Guadagnolo; Andrew J Bishop; Wei-Lien Wang; John M Slopis; Ian E McCutcheon; Alexandar J Lazar; Keila E Torres
Journal:  J Neurosurg       Date:  2016-04-01       Impact factor: 5.115

10.  Rare primary malignant peripheral nerve sheath tumor of the left testis: A case report.

Authors:  Dongdong Liu; Yi Mu; Pan Chen; Bangwei Che; Zheming Li; Yili Zhao; Fa Sun; Kaifa Tang
Journal:  Mol Clin Oncol       Date:  2021-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.